Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Ionis Pharmaceuticals (IONS) reported a Q3 loss of $0.95 per share, which was better than the Zacks Consensus Estimate of a $1.16 loss. This is an improvement from the $1.03 loss per share reported a year ago.
November 06, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ionis Pharmaceuticals reported a Q3 loss of $0.95 per share, beating the Zacks Consensus Estimate of a $1.16 loss. This is an improvement from the previous year's $1.03 loss per share.
The better-than-expected earnings report, with a smaller loss than anticipated, is likely to have a positive short-term impact on Ionis Pharmaceuticals' stock price. The improvement from the previous year's loss also adds to the positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100